The edge of biotech hedge funds: predictable trials, LLMs and subtle information extraction

owl_posting · x · 2026-11-21

Abhishaike Mahajan's first Works in Progress column examines where biotech hedge funds' edge comes from (Baker Brothers, Deerfield, OrbiMed each manage $15B+):

Related event: New Column Examines How Biotech Hedge Funds Beat the Market(2 posts)→

Original post →

More from Venture

Venture channel →